Analgesic-Releasing Polymer Wound Dressing for Sustained Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing wound dressings fail to provide effective, sustained pain relief for partial thickness skin injuries without resorting to addictive prescription opiates, and frequent dressing changes cause significant pain and discomfort.
Innovation Solution
A porous biosynthetic polymer film impregnated with a local analgesic, such as bupivacaine, that provides a sustained release over several days, allowing the dressing to remain in place until new epithelial tissue grows, minimizing pain and reducing the need for dressing changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent dressing changes are performed to manage partial thickness skin injuries, then wound protection is maintained, but patient pain and discomfort increase significantly
Solution Approach 1:
The analgesic is pre-loaded into the biosynthetic polymer film before the dressing is applied to the wound. This preliminary action ensures that pain relief is available from the moment of application, eliminating the need for repeated painful dressing changes to manage pain during the healing process.
Solution Approach 2:
The biosynthetic polymer film provides continuous analgesic release over the entire healing period (up to 14 days or longer), maintaining both wound protection and pain relief continuously. This eliminates the intermittent disruption caused by frequent dressing changes while ensuring uninterrupted therapeutic action.
2Object-affected harmful factors
If prescription opiates are used to treat severe pain from skin injuries, then pain relief is effective, but addiction and systemic toxicity occur
Solution Approach 1:
The invention extracts the pain relief function from systemic opiates and implements it locally at the wound site through the biosynthetic polymer film. This local delivery provides effective analgesia while eliminating the systemic circulation and associated risks of addiction and systemic toxicity.
Solution Approach 2:
The biosynthetic polymer film acts as an intermediary carrier that delivers the analgesic directly to the wound site and surrounding tissue. This intermediary delivery system provides controlled local release, preventing the analgesic from entering systemic circulation and causing addiction or systemic toxicity while maintaining effective pain relief at the target site.
3Reliability
If a durable non-dissolvable polymer is used for the wound dressing, then wound protection is maintained over extended healing time, but the dressing requires manual removal which may cause pain
Solution Approach 1:
The biosynthetic polymer film is designed with predetermined degradation characteristics that allow it to maintain structural integrity and provide wound protection throughout the healing period, then automatically degrade and detach when no longer needed. This preliminary design eliminates the need for manual removal and associated pain.
Solution Approach 2:
The biosynthetic polymer film undergoes parameter changes over time, specifically degradation and loss of mechanical strength, as a function of time and wound healing progress. This parameter change allows the dressing to transition from a durable protective state to a detachable state, enabling painless removal through natural degradation rather than manual intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The analgesic-releasing wound dressing offers prolonged pain relief without systemic toxicity, maintains wound protection, and allows for painless removal when healing is complete, reducing the need for opioid use and minimizing patient discomfort.
Implementation Method 1
provide sustained release of the local analgesic... over an extended period of time
Data Source
AI summary
A wound dressing including a porous biosynthetic polymer film comprising a poly(lactide-co-caprolactone) (“PLC”) copolymer or other suitable polymer matrix, and a local analgesic loaded therein, to provide pain relief over an extended period of time (e.g., for 5-7 days), e.g., for healing of a partial thickness dermal injury. The PLC copolymer may have a particular lactide/caprolactone molar ratio (e.g., from 2:1 to 9:1) to ensure slow, sustained release of the bupivacaine or other analgesic. The dressing may provide a water vapor transmission rate from 1000 g/m2·day to 3000 g/m2·day to facilitate fast healing and regrowth of new epithelial tissue beneath the dressing. The dressing is configured to remain positioned over the dermal injury, providing wound protection for about 14 days, after which is simply debrides away, falls off, or is easily and painlessly removed, once new epithelial tissue regrows.